Business Description
ClearPoint Neuro Inc
NAICS : 339112
SIC : 3841
ISIN : US18507C1036
Total Employee Number:
172Compare
Compare
Traded in other countries / regions
CLPT.USA Index Membership
Russell 2000Russell 3000Russell 2000Russell 2000Russell 3000 IPO Date
2012-05-18Description
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.46 | |||||
Equity-to-Asset | 0.12 | |||||
Debt-to-Equity | 5.93 | |||||
Debt-to-EBITDA | -2.5 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -0.27 | |||||
Beneish M-Score | 6.53 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 15.4 | |||||
3-Year EBITDA Growth Rate | -4.6 | |||||
3-Year EPS without NRI Growth Rate | -9.8 | |||||
3-Year FCF Growth Rate | -6.4 | |||||
3-Year Book Growth Rate | -14 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 20.84 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 49.98 | |||||
9-Day RSI | 51.75 | |||||
14-Day RSI | 50.92 | |||||
3-1 Month Momentum % | 34.38 | |||||
6-1 Month Momentum % | 6.36 | |||||
12-1 Month Momentum % | 45.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.74 | |||||
Quick Ratio | 3.89 | |||||
Cash Ratio | 2.85 | |||||
Days Inventory | 178.34 | |||||
Days Sales Outstanding | 55.02 | |||||
Days Payable | 36.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.1 | |||||
Shareholder Yield % | -9.46 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 62.61 | |||||
Operating Margin % | -73.42 | |||||
Net Margin % | -81.76 | |||||
EBITDA Margin % | -60.47 | |||||
FCF Margin % | -74.01 | |||||
OCF Margin % | -71.39 | |||||
ROE % | -185.33 | |||||
ROA % | -43.09 | |||||
ROIC % | -80.53 | |||||
3-Year ROIIC % | -24.39 | |||||
ROC (Joel Greenblatt) % | -151.52 | |||||
ROCE % | -41.3 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 10.64 | |||||
PB Ratio | 43.89 | |||||
EV-to-EBIT | -17.15 | |||||
EV-to-EBITDA | -19.68 | |||||
EV-to-Revenue | 11.9 | |||||
EV-to-FCF | -16.08 | |||||
Price-to-GF-Value | 1.07 | |||||
Price-to-Median-PS-Value | 1.48 | |||||
Earnings Yield (Greenblatt) % | -5.83 | |||||
FCF Yield % | -6.68 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CLPT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ClearPoint Neuro Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 42.279 | ||
| EPS (TTM) ($) | -1.18 | ||
| Beta | 1.8017 | ||
| 3-Year Sharpe Ratio | 0.59 | ||
| 3-Year Sortino Ratio | 1.42 | ||
| Volatility % | 131.07 | ||
| 14-Day RSI | 50.92 | ||
| 14-Day ATR ($) | 0.831165 | ||
| 20-Day SMA ($) | 14.65825 | ||
| 12-1 Month Momentum % | 45.13 | ||
| 52-Week Range ($) | 8.27 - 30.0999 | ||
| Shares Outstanding (Mil) | 30.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ClearPoint Neuro Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ClearPoint Neuro Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 17:00 | In 78 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 77 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-03 16:30 | 14.94 (+0.27%) | ||
| Second quarter earnings results for 2026 | 2026-08-03 | 14.94 (+0.27%) | ||
| General meeting for 2026 | 2026-05-20 10:00 | 11.17 (+0.90%) | ||
| First quarter earnings conference call for 2026 | 2026-05-13 16:30 | 12.64 (+4.12%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 12.64 (+4.12%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-17 16:30 | 11.03 (+0.27%) | ||
| Annual report for 2025 | 2026-03-17 | 11.03 (+0.27%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-17 | 11.03 (+0.27%) |
Show
Entries
ClearPoint Neuro Inc Frequently Asked Questions
What is ClearPoint Neuro Inc(CLPT)'s stock price today?
The current price of CLPT is $15.36. The 52 week high of CLPT is $30.10 and 52 week low is $8.27.
When is next earnings date of ClearPoint Neuro Inc(CLPT)?
The next earnings date of ClearPoint Neuro Inc(CLPT) is 2026-11-06 Est..
Does ClearPoint Neuro Inc(CLPT) pay dividends? If so, how much?
ClearPoint Neuro Inc(CLPT) does not pay dividend.
Guru Commentaries on NAS:CLPT
Cedar Grove Capital Management
Bullish
2026 Q2
Q226 CGCM Quarterly Letter
What the manager wrote
We initiated appropriately sized positions in QURE and CLPT to reflect the speculative nature of the opportunity. The thesis centered on a potentially more constructive regulatory environment within the FDA’s Center for Biologics Evaluation and Research and the possibility of renewed regulatory pathways for certain neurological therapies. Subsequent FDA feedback indicated that QURE could submit an application for accelerated approval following prior regulatory uncertainty. We expect the filing no earlier than late Q3; if accepted, an FDA decision could potentially occur before year-end. We will continue to monitor both the regulatory process and the implications for CLPT.
Press Release
Articles on ClearPoint Neuro Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers